Galecto Inc. (GLTO): Price and Financial Metrics
GET POWR RATINGS... FREE!
GLTO Stock Price Chart Interactive Chart >
GLTO Price/Volume Stats
| Current price | $2.30 | 52-week high | $2.80 |
| Prev. close | $2.24 | 52-week low | $1.04 |
| Day low | $2.08 | Volume | 85,667 |
| Day high | $2.40 | Avg. volume | 68,765 |
| 50-day MA | $1.59 | Dividend yield | N/A |
| 200-day MA | $1.81 | Market Cap | 58.84M |
Galecto Inc. (GLTO) Company Bio
Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.
Latest GLTO News From Around the Web
Below are the latest news stories about GALECTO INC that investors may wish to consider to help them evaluate GLTO as an investment opportunity.
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual MeetingIntermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients GB2064 is an oral inhibitor of the collagen cross-linking enzyme LOXL-2, which is linked to myelofibrosis BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibros |
Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowGalecto, Inc. (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong BuyGalecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning! |
GLTO Price Returns
| 1-mo | 100.00% |
| 3-mo | 17.95% |
| 6-mo | 20.42% |
| 1-year | -4.17% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 100.00% |
| 2022 | -62.05% |
| 2021 | -75.78% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...